Healthcare provider profile · identity verified

Calin Kirk, MD

Family Practice · JAY, OK · NPI 1255718607

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	149	55
Losartan Potassium	Losartan Potassium	142	46
Gabapentin	Gabapentin	141	35
Synthroid	Levothyroxine Sodium	137	32
Fluticasone Propionate	Fluticasone Propionate	115	38
Amlodipine Besylate	Amlodipine Besylate	113	37
Omeprazole	Omeprazole	107	44
Albuterol Sulfate Hfa	Albuterol Sulfate	104	33
Ozempic	Semaglutide	103	18
Tamsulosin Hcl	Tamsulosin Hcl	74	24
Lisinopril	Lisinopril	71	28
Tramadol Hcl	Tramadol Hcl	70	15
Metformin Hcl Er	Metformin Hcl	68	17
Eliquis	Apixaban	61	17
Montelukast Sodium	Montelukast Sodium	61	19
Metoprolol Tartrate	Metoprolol Tartrate	54	13
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	53	suppressed
Diclofenac Sodium	Diclofenac Sodium	53	20
Metoprolol Succinate	Metoprolol Succinate	49	18
Famotidine	Famotidine	48	16
Carvedilol	Carvedilol	46	16
Meloxicam	Meloxicam	46	13
Prednisone	Prednisone	46	25
Furosemide	Furosemide	45	18
Pregabalin	Pregabalin	45	suppressed
Clopidogrel	Clopidogrel Bisulfate	44	18
Spiriva Respimat	Tiotropium Bromide	43	suppressed
Trazodone Hcl	Trazodone Hcl	43	13
Easy Touch Pen Needle	Pen Needle, Diabetic	40	12
Baclofen	Baclofen	39	16
Citalopram Hbr	Citalopram Hydrobromide	38	12
Ibuprofen	Ibuprofen	36	11
Hydrochlorothiazide	Hydrochlorothiazide	35	15
Jardiance	Empagliflozin	35	11
Dicyclomine Hcl	Dicyclomine Hcl	31	suppressed
Potassium Chloride	Potassium Chloride	31	12
Pioglitazone Hcl	Pioglitazone Hcl	30	suppressed
Simvastatin	Simvastatin	27	suppressed
Vitamin D2	Ergocalciferol (Vitamin D2)	27	12
Alendronate Sodium	Alendronate Sodium	25	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	25	suppressed
Metformin Hcl	Metformin Hcl	24	11
Bupropion Xl	Bupropion Hcl	23	suppressed
Ondansetron Odt	Ondansetron	23	suppressed
Duloxetine Hcl	Duloxetine Hcl	22	suppressed
Repatha Sureclick	Evolocumab	21	suppressed
Chlorthalidone	Chlorthalidone	20	suppressed
Fosinopril Sodium	Fosinopril Sodium	20	suppressed
Glipizide Er	Glipizide	19	suppressed
Toujeo Solostar	Insulin Glargine,hum.Rec.Anlog	19	suppressed
Hydroxyzine Hcl	Hydroxyzine Hcl	18	suppressed
Memantine Hcl	Memantine Hcl	18	suppressed
Spironolactone	Spironolactone	18	suppressed
Rosuvastatin Calcium	Rosuvastatin Calcium	17	suppressed
Wixela Inhub	Fluticasone Propion/Salmeterol	17	suppressed
Xarelto	Rivaroxaban	17	suppressed
Allopurinol	Allopurinol	16	suppressed
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	16	15
Buspirone Hcl	Buspirone Hcl	16	suppressed
Dilantin	Phenytoin Sodium Extended	16	suppressed
Diltiazem 24hr Er	Diltiazem Hcl	16	suppressed
Invokana	Canagliflozin	15	suppressed
Lactulose	Lactulose	15	suppressed
Lidocaine	Lidocaine	15	suppressed
Sertraline Hcl	Sertraline Hcl	15	suppressed
Warfarin Sodium	Warfarin Sodium	15	suppressed
Aripiprazole	Aripiprazole	14	suppressed
Bumetanide	Bumetanide	14	suppressed
Fenofibrate	Fenofibrate	14	suppressed
Mirtazapine	Mirtazapine	14	suppressed
Mupirocin	Mupirocin	14	12
Donepezil Hcl	Donepezil Hcl	13	suppressed
Finasteride	Finasteride	13	suppressed
Glipizide Xl	Glipizide	13	suppressed
Levemir	Insulin Detemir	13	suppressed
Methotrexate	Methotrexate Sodium	13	suppressed
Testosterone Cypionate	Testosterone Cypionate	13	suppressed
Toujeo Max Solostar	Insulin Glargine,hum.Rec.Anlog	13	suppressed
Acetaminophen-Codeine	Acetaminophen With Codeine	12	suppressed
Combivent Respimat	Ipratropium/Albuterol Sulfate	12	suppressed
Mounjaro	Tirzepatide	12	suppressed
Entresto	Sacubitril/Valsartan	11	suppressed
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	11	suppressed
Rybelsus	Semaglutide	11	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error